Buy back
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts more than Nifty 100 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences Ltd's Board has approved a buyback of up to 95,65,217 fully paid-up equity shares (0.95% of total paid-up capital) at INR 1,150 per share. The total buyback size is INR 1,100 crores, representing 5.16% and 3.84% of standalone and consolidated free reserves respectively. The buyback will be conducted via the tender offer route, open to all equity shareholders including promoters on a proportionate basis. The record date for determining eligible shareholders is May 29, 2026. A buyback committee has been formed to oversee the process. Pre-buyback shareholding shows promoters hold 74.995% of the company.
The buyback offers shareholders a chance to exit at INR 1,150 per share, which is significantly above the current market price, providing a positive signal for stock price support near that level. This is a shareholder-friendly move returning capital while potentially enhancing per-share metrics.